BACKGROUND: Despite controversy surrounding its benefit, the use of concomitant chemoradiotherapy (CCRT) in patients with oropharyngeal squamous cell carcinoma (OPSCC) who are aged > 70 years is increasing. However, to the authors' knowledge, few studies to date have compared the outcomes of different systemic treatments in this population. METHODS: Records from 74 patients aged 70 years with stage III to stage IVB OPSCC who were undergoing CCRT from 2002 to 2013 at a single institution were reviewed. Patients were stratified according to the systemic therapy received, including cisplatin, carboplatin with either 5-fluorouracil or paclitaxel (CARB), or cetuximab to compare oncologic outcome and toxicity. RESULTS: The median follow-up was 36 months. The median age of the patients was 75.3 years (range, 70-91 years), with significantly older patients receiving cetuximab (P 5.03). A total of 28, 20, and 26 patients, respectively, received CCRT with cisplatin, CARB, and cetuximab. RT interruptions of > 1 day were needed in 4% of patients receiving cisplatin, 20% of patients receiving CARB, and 15% of patients receiving cetuximab (P 5.19). Unplanned hospitalizations during CCRT occurred in 25%, 55%, and 58%, respectively, of patients receiving cisplatin, CARB, and cetuximab (P 5.03). There were 2 treatment-related deaths, both of which occurred among the patients who were treated with cetuximab. At 5 years, locoregional control was achieved in 100%, 88%, and 60% (P<.001), respectively, and the overall survival rate was 87%, 61%, and 47% (P 5.03), respectively, among patients treated with cisplatin, CARB, and cetuximab. CONCLUSIONS: Toxicity from CCRT remains a challenge for older adults with OPSCC. Herein, the authors found no evidence that this toxicity was mitigated by treatment with cetuximab. Nevertheless, a subset of patients aged 70 years appear to tolerate cisplatin-based treatment with acceptable toxicity and excellent outcomes. Further identification of this patient subgroup is crucial to optimize therapy for older patients with OPSCC. Cancer 2017;123:1345-53.
INTRODUCTION
The management of older adult patients with head and neck cancer is one of the most daunting challenges in all of oncology. Treatment intensification approaches that have improved survival for patients with head and neck cancer who are undergoing definitive radiotherapy (RT), such as concomitant platinum-based chemoradiation, 1 cetuximab-based bioradiation, 2 and altered fractionation, 3 have demonstrated no survival benefit in patients aged >70 years. Although there may be biologic and microenvironmental differences in head and neck cancers arising in older adults, the most likely explanation for the lack of benefit observed with these treatments in these individuals is that this population has difficulty tolerating intense multimodality regimens. For example, increasing age has been associated with an increased risk of severe late toxicity for patients undergoing concomitant chemoradiotherapy (CCRT). 4 Furthermore, older patients have been observed to have higher rates of acute toxicity from cisplatin-based chemotherapy, in comparison with younger patients.
Nevertheless, the older adult population is heterogeneous, comprising both relatively fit and relatively frail individuals with varying degrees of medical comorbidities. This is particularly relevant for cancers arising from the oropharynx in the modern era, given the rapidly changing epidemiology of this disease. For example, human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPCs) often occur in otherwise healthy patients with minimal to no smoking history, whereas HPV-negative tumors most often occur in life-long smokers and drinkers with a high comorbidity burden. Although initial studies have suggested that HPV-associated cancers predominantly occur in patients aged <60 years, 6 a recent study found that approximately 65% of oropharyngeal tumors from patients aged 70 years had highrisk HPV DNA, 7 and the incidence of OPSCC in patients aged 65 years is increasing at a rate that is identical to what has been observed in younger patients over the past decade. 8 Furthermore, the data from clinical trials demonstrating a lack of benefit for treatment intensification in older patients have been derived primarily from an era before the widespread adoption of intensity-modulated RT (IMRT), which is capable of decreasing late adverse treatment sequelae by delivering highly conformal RT dose distributions. 9 Thus, it is possible that older patients derive a greater benefit from multimodality therapy in the modern era due to both biologic and therapeutic factors. However, recent database studies from the National Cancer Data Base and the Surveillance, Epidemiology, and End Results-Medicare database have reached conflicting conclusions. 10, 11 Despite these uncertainties, the majority of older patients with head and neck cancer in the United States receive CCRT, 12 with the use of cetuximab dramatically increasing since the publication of the IMCL-9815 trial in 2006. 13 There are limited data regarding the efficacy and toxicity of CCRT specifically in patients with OPSCC in the modern era, or comparing different systemic regimens in this population. We hypothesized that tremendous heterogeneity with regard to tolerance to multimodality therapy among older adults with OPSCC persists even in the era of IMRT and increasing HPV rates, and that patients deemed unfit for concomitant cisplatin still may be at high risk of toxicity with alternative regimens. In the current study, we retrospectively reviewed all patients aged 70 years with locally advanced oropharyngeal squamous cell carcinoma (OPSCC) who were treated with definitive IMRT and concomitant systemic therapy at the study institution. In the current study, we report rates of hospitalization, treatment completion, and cancer-specific outcomes among groups of patients selected to receive different concomitant systemic treatments, including cisplatin, carboplatin doublets, and cetuximab.
MATERIALS AND METHODS

Patient Selection
A total of 85 consecutive patients aged 70 years who were diagnosed with locally advanced (AJCC 7th edition stage III-IVB) OPSCC from 2002 to 2013 at a single institution were reviewed retrospectively. Four patients were treated with RT alone, 6 received induction chemotherapy, and 1 patient received single-agent paclitaxel; these patients were excluded from the current analysis. The remaining 74 patients formed the cohort of the current study. Institutional Review Board permission was granted before data acquisition and analysis.
Treatment RT techniques have been described previously.
14 Briefly, all patients were treated with IMRT. Immobilization was performed using a thermoplastic mask with or without shoulder immobilization in the supine position. Computed tomography images were acquired with 3-mm thickness, and target volumes and organs at risk were delineated by the treating radiation oncologist. Macroscopic disease was treated to 70 Gray (Gy) in 2.12 Gy per fraction. 59.4 Gy in 1.8 Gy per fraction and 54 Gy in 1.64 Gy per fraction were delivered to areas considered to be at high-risk and low-risk of harboring microscopic disease, respectively. The type of concomitant systemic therapy was chosen at the discretion of the treating medical oncologist after a multidisciplinary discussion.
Endpoints
The primary purpose of the current study was to assess objective measures of treatment toxicity in patients aged 70 years, including unplanned hospitalizations during treatment, completion of RT and systemic therapy, and percutaneous endoscopic gastrostomy (PEG) tube dependence, defined as the presence of a PEG tube >12 months after completing CCRT. A treatment break was considered an unplanned interruption of RT lasting >1 day. Receipt of systemic therapy was dichotomized into patients receiving at least 6 weeks of treatment (eg, 2 doses of bolus cisplatin given every 3 weeks or 6 doses of weekly chemotherapy or cetuximab) versus those receiving less than this, based on data from the Radiation Therapy Oncology Group 0129 trial suggesting that the receipt of 2 cycles of bolus cisplatin was associated with improved outcome. 15 Acute and late toxicity also were quantified. Toxicity was graded according to the Common Toxicity Criteria for Adverse Events (version 4.0). Late toxicities were defined as those occurring 90 days after the completion of treatment.
Statistical Analysis
Baseline characteristics were compared using Fisher exact tests for categorical variables and Kruskal-Wallis tests for noncategorical and continuous variables. Logistic regression was used to determine variables predictive of the receipt of cisplatin. The estimated probabilities of locoregional control (LRC), freedom from distant metastasis (FFDM), and overall survival (OS) were calculated according to the Kaplan-Meier method and survival curves were compared used the log-rank test. For analysis of LRC and FFDM, death without LRC/FFDM was regarded as independent censoring. For cancer-specific mortality (CSM), a competing risks cumulative incidence methodology was used. P values reported in the current study refer to comparisons across all 3 treatments unless stated explicitly to be pairwise. For pairwise comparisons of treatments in time-to-event analysis of LRC, FFDM, and OS only, P values < .017 were considered to be statistically significant after applying the Bonferroni correction for multiple comparisons. Time to events was calculated from the initiation of RT.
RESULTS
Baseline patient characteristics are summarized in Table 1 . Overall, 28 patients received cisplatin, 20 received a carboplatin doublet (carboplatin/5-fluorouracil or carboplatin/paclitaxel), and 26 received cetuximab. Of those patients receiving cisplatin, 23 (82%) received bolus cisplatin (100 mg/m 2 every 3 weeks), although 6 of these patients were switched to weekly cisplatin (3 patients) or carboplatin and paclitaxel (3 patients) after the first cycle. There was a significant difference in age noted among the subgroups (P 5 .03), with patients receiving cisplatin (median age, 73 years [range, 70-80 years]) or carboplatin doublets (median age, 74.8 years [range, 70-81 years]) more likely to be younger than those receiving cetuximab (median age, 77.5 [range, 70-91 years]). Furthermore, approximately 4% of patients receiving platinum-based chemoradiation were aged 80 years, in comparison with 35% of patients receiving cetuximab. Significant differences with regard to year of diagnosis also were noted when comparing the 3 groups (P<.001), with those patients treated with carboplatin doublets most likely to be treated before 2006, whereas patients diagnosed after 2006 were more likely to receive cisplatin or cetuximab. Patients receiving cetuximab were significantly less likely to be married in comparison with patients receiving platinum-based chemotherapy (P 5 .04). Only 23 of 74 patients (31%) had p16 testing available. Of these, 10 of 12 patients receiving cisplatin for whom p16 testing was available (83%) were p16 positive, in comparison with 4 of 5 patients treated with carboplatin doublets (80%) and 3 of 6 patients receiving cetuximab (50%). There was no significant different noted with regard to Karnofsky performance status (KPS) (P 5 .24) or Charlson Comorbidity Index (P 5 .71). Tumor classification (P 5 .82), lymph node classification (P 5 .97), sex (P 5 .94), and anatomic site (P 5 .95) also were found to be similar among all 3 groups. The median follow-up for the entire cohort was 36 months.
Predictors of receipt of cisplatin are shown in Table  2 . On univariate analysis, the only predictor of receipt of cisplatin was younger age (odds ratio, 0.85; P 5 .01).
Toxicity outcomes are described in Table 3 . Overall, RT was completed as planned in 100%, 95%, and 96%, respectively, of patients receiving cisplatin, carboplatin doublets, and cetuximab. Although RT treatment breaks lasting >1 day were less common among patients receiving cisplatin (4%) compared with those receiving carboplatin doublets (20%) or cetuximab (15%), this did not reach statistical significance (P 5 .19). At least 6 weeks of concomitant systemic therapy was administered to 82%, 90%, and 85%, respectively, of patients receiving cisplatin, carboplatin doublets, or cetuximab. Moderate weight loss was common in all groups, with a median weight loss of 5.4 kg, 3.3 kg, and 5.4 kg, respectively, noted with each systemic therapy (P 5 .24). Unplanned hospitalizations were required in 25% of patients receiving cisplatin, in comparison with 55% and 58%, respectively, of patients treated with carboplatin doublets or cetuximab (P 5 .03). Overall grade 3 to 4 acute toxicity was less for patients receiving cisplatin compared with those receiving other systemic treatments (29% vs 65% vs 58%; P 5 .03). Two treatment-related deaths occurred among 26 patients receiving cetuximab (8%), versus none in patients receiving cisplatin-based or carboplatin-based treatment. Acute kidney injury was significantly more common (P < .001) in patients receiving cisplatin (39%) in comparison with patients receiving carboplatin doublets (0%) or cetuximab (8%). However, no patient experienced irreversible kidney damage. There was no significant difference in the percentage of patients requiring PEG tubes for >12 months after completing RT.
The LRC rate at 5 years for patients undergoing cisplatin-based chemoradiation was 100%, in comparison with 88% (pairwise P 5 .08) and 60% (pairwise P<.001), respectively, for patients receiving carboplatin doublet-based chemoradiation and cetuximab-based bioradiation (Fig. 1A) . There was a trend toward better LRC when comparing carboplatin doublet therapy with cetuximab, but this did not reach statistical significance after applying the Bonferroni correction for multiple hypothesis testing (pairwise P 5 .05). By contrast, there was no significant difference noted with regard to the 5-year FFDM rate in any group (P>.2 for all pairwise comparisons) (Fig. 1B) . The CSM rate at 5 years was 4%, 12%, and 35%, respectively, for patients receiving cisplatin, carboplatin doublets, and cetuximab (Fig. 1C) . There was no statistical difference observed when comparing CSM in patients receiving cisplatin versus those receiving carboplatin doublets (pairwise P 5 .36), whereas patients receiving cisplatin had significantly improved CSM compared with patients receiving cetuximab (pairwise P 5 .015). The 5-year OS rate was 87% for patients receiving cisplatin-based chemoradiation, in comparison with 61% (pairwise P 5 .50) and 47% (pairwise P 5 .005), respectively, for patients treated with carboplatin doublet-based chemoradiation and cetuximab-based bioradiation (Fig. 1D) . The median OS was 78 months, 92 months, and 43 months, respectively, for patients treated with cisplatin, carboplatin doublets, and cetuximab.
DISCUSSION
To the best of our knowledge, the current study is the largest series to date focusing exclusively on patients aged 70 years with locally advanced OPSCC undergoing definitive chemoradiation exclusively with IMRT. We found that outcomes and toxicity varied widely for patients receiving cisplatin, carboplatin doublets, or cetuximab concomitantly with RT. For example, of the 85 patients with locally advanced OPSCC who were age 70 years and diagnosed during the time period of this study, 28 (33%) were determined to be medically fit for cisplatin-based chemoradiation by the treating medical oncologist. These patients tended to be younger than patients receiving other systemic therapies, although there was no statistically significant difference noted with regard to KPS or baseline comorbidity. Outcomes in this subgroup were exceptional, with a 5-year LRC rate of 100% and an OS rate of 87%. The high OS in this group speaks in part to their overall robust health status, which may not have been captured in our performance measures. Moreover, toxicity was acceptable in patients aged 70 years who were receiving cisplatin-based therapy, with 96% completing RT without a break of >1 day, 75% completing treatment without requiring hospital admission for toxicity, and 82% receiving at least 6 weeks of systemic therapy during RT (200 mg/m 2 of cisplatin). It is notable that nearly 40% of these patients had acute kidney injury, defined as a 50% increase in creatinine over baseline, but no patient experienced long-term renal impairment. Although p16 immunohistochemistry was only available for 12 patients receiving cisplatin, 10 of these individuals were found to be positive (83%). This suggests that the subgroup of patients receiving cisplatin may have harbored primarily HPV-associated OPSCCs, similar to what would be expected in a younger population, although the fact that less than one-half of patients undergoing cisplatin-based chemoradiation underwent p16 testing limits our ability to draw clear conclusions. Nevertheless, it is possible that older patients with HPVassociated tumors are better able to tolerate intense multimodality therapy compared with older patients with HPV-negative tumors, who have often been life-long smokers and drinkers. This is especially germane given that the incidence of HPV-associated OPSCC appears to be increasing dramatically in the population aged 65 years. 8 In contrast to the relatively fit older patients treated with cisplatin, the majority of the least medically fit patients received concomitant cetuximab, especially given that RT alone was only administered to 5% of patients aged 70 years who had locally advanced OPSCC at the study institution during this time period. These patients were significantly older than those receiving concomitant platinum-based chemoradiation (35% vs 5% were aged 80 years; P 5 .003). In addition, patients receiving cetuximab were significantly less likely to be married, which has been demonstrated to be a negative prognostic factor in older adults with head and neck cancer. 16 Results in the population receiving cetuximab were markedly worse, with a 5-year LRC rate of 60% and an OS rate of 47%. Furthermore, although 85% of patients receiving cetuximab were able to complete RT without a break of >1 day and received at least 6 weekly doses of cetuximab, 58% required unplanned hospitalization during treatment and 2 patients (8%) experienced grade 5 toxicity during or immediately after RT compared with no treatment-related deaths reported among other patients in the current series. It is certain that sicker, older patients tend to be routed to cetuximab therapy at the study institution, in part explaining their poor outcomes and tolerance of therapy. Nonetheless, we believe the results of the current study provide little evidence that cetuximab-based bioradiotherapy is either efficacious or well tolerated in older patients deemed unfit for platinum-based chemoradiotherapy. It is important to note that although the use of cetuximab-based bioradiation in older adults has markedly increased since the publication of the IMCL-9815 trial, 17 this trial actually demonstrated no benefit for cetuximab in patients aged 65 years. 2 Thus, the practice of administering cetuximab to this population should be scrutinized carefully.
It is important to emphasize that the objective of the current study was not to directly compare the effects of various systemic regimens for combined modality therapy in patients aged 70 years with OPSCC, although there certainly could be inherent differences in adverse sequelae and efficacy from various treatments in this population. Rather, we believe the current study results are primarily a testament to the heterogeneity of the older adult population. Recognizing this heterogeneity, it is important to develop scientifically validated tools for assessing the fitness of an older patient to receive concomitant head and neck chemoradiation beyond simply age, performance status, and the "eyeball test." It is possible that standard geriatric assessment tools, such as the Comprehensive Geriatric Assessment, may be helpful in this regard. 18 The Comprehensive Geriatric Assessment is a multidimensional evaluation tool that incorporates comorbidity, performance status, social support, nutrition, cognition, and psychological status to assess the "functional age" of a patient. However, the length and complexity of this assessment have limited its widespread adoption. In addition, although predictive models for toxicity from chemotherapy in older adults have been developed, 19 to our knowledge less is known regarding predictors of toxicity specifically after chemoradiation for head and neck
cancer. In what to our knowledge is one of the largest geriatric chemoradiation studies published to date, a KPS 80, Charlson Comorbidity Index 3, and weekly platinum were associated with lower rates of treatment completion for patients undergoing chemoradiation. 20 An abnormal glomerular filtration rate and lower body mass index were found to be associated with high rates of hospitalization. 20 In our study, we were not able to test a KPS 80 and Charlson Comorbidity Index 3 as toxicity predictors because we had very few patients in these categories. Significant work remains to develop clinically validated tools for treatment selection in the geriatric population with head and neck cancer.
Although several previous studies have reported outcomes in older adults undergoing chemoradiation for head and neck cancer, [20] [21] [22] [23] [24] to the best of our knowledge these studies have either been relatively small, 21, 23, 24 included multiple anatomic subsites, [20] [21] [22] [23] treated at least some patients without IMRT, 20, 21, 23 or delivered systemic regimens and fractionation schedules that are not widely used. 22 By contrast, the current study included only patients aged 70 years with stage III to IVB OPSCC and who were receiving IMRT with platinum-based or cetuximab-based systemic therapy. Another strength of the current study is that the vast majority of patients (81 of 85 patients; 95%) diagnosed with locally advanced head and neck cancer at the study institution during the time period of the current study received concomitant systemic therapy. Thus, although there was significant selection bias in terms of the specific type of systemic therapies that patients received, we believe the population included herein is a good representation of the entire spectrum of patients aged 70 years presenting with locally advanced OPSCC at the study institution over more than a decade. In addition, all patients in the current study were treated with IMRT, which currently is the standard of care in head and neck radiation oncology given its ability to decrease late toxicity, 9 and therefore is more representative of the toxicities encountered in modern radiation oncology practice than older series using conventional treatment techniques. Nevertheless, even with modern RT techniques and subspecialty expertise, delivering CCRT in older adults remains challenging in modern practice. Although the vast majority of patients were able to complete treatment without interruptions, nearly 50% of patients required hospitalization during treatment.
There are significant limitations to our data set, including its retrospective nature and the limited numbers of patients receiving each treatment, thereby precluding multivariate analyses or propensity score matching.
Furthermore, the fact that systemic treatments were chosen at the discretion of the treating medical oncologist created inherently disparate subgroups for each regimen, making direct comparisons challenging. The unavailability of p16 data for the majority of patients also complicated the analysis of oncologic outcomes given the substantial prognostic impact of this biomarker in patients with OPSCC. 25 In addition, all patients were treated within an urban, academic, tertiary oncology hospital by subspecialists with expertise in head and neck radiation oncology, medical oncology, or supportive care. Therefore, it is possible that the results of the current study may not be generalizable to community cancer centers or areas of the country with higher rates of HPVnegative OPSCC in older patients. Graded toxicity also is by nature subjective, and assessments of toxicity may vary substantially between different radiation oncologists. For this reason, we chose to focus predominantly on objective measures such as hospital admission, treatment completion, and treatment-related mortality for the current study. Furthermore, certain important later toxicity outcomes, such as aspiration pneumonia, are common in older patients after chemoradiation but were not assessed in the current study. 26 Nevertheless, several important conclusions can be drawn from the current study. First, we believe that the reluctance to administer cisplatin-based chemoradiation to patients aged 70 years with OPSCC needs to be reconsidered for appropriately selected patients. Although the Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC) demonstrated no evidence of survival benefit for CCRT among the subgroup of patients aged >70 years, the trials included in that analysis mostly were decades old, used conventional RT techniques expected to be associated with higher late toxicity, and predominantly enrolled patients with HPV-negative tumors. 1 In the current series, which was performed among a highly selected group of patients deemed medically fit for cisplatin-based treatment, all of whom received IMRT and likely had mostly p16-positive tumors, the outcomes were excellent and toxicity was manageable. This is consistent with several other retrospective series suggesting that CCRT may be feasible in patients aged 70 years. 10, 19, [27] [28] [29] Second, we believe that administering cetuximab to the geriatric population deemed unfit for platinum-based chemotherapy, although common, is not supported by current evidence 2 and likely does not represent an efficacious, welltolerated, or cost-effective approach. Third, prospective trials defining the optimal treatment for the older adult population are critical given the increasing incidence of OPSCC in this population and the aging of the US population. 8, 30 Finally, we believe that, whenever possible, older patients with OPSCC should be treated at highvolume academic centers with expertise in managing this population and access to supportive ancillary services such as geriatrics, nutrition, speech and swallowing, and palliative care. 31, 32 The data from the current study support the hypothesis that patients aged 70 years with OPSCC comprise an extremely heterogeneous group in the HPV era, with variable tolerance to multimodality radiation-based treatment. However, there is unequivocally a subgroup of older patients who are able to tolerate cisplatin-based chemoradiation with acceptable toxicity, and have excellent oncologic outcomes. Conversely, the results of the current study demonstrated relatively poor tolerance and poor oncologic outcomes with cetuximab-based bioradiation among older patients presumably deemed unfit for platinum-based treatment. Further prospective studies and the identification of patient-related variables that predict for the ability of a patient aged 70 years to tolerate CCRT are imperative.
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